Abstract
As an important pro-inflammatory cytokine, interleukin-1beta (IL-1β) participates in a variety of physiological and pathological responses. In order to obtain higher yielded recombinant human interleukin-1 beta (rhIL-1β), we cloned hIL-1β cDNA sequences based on the coding sequence of human mature IL-1β. After recombinant pPICZαA/hIL-1β was separated and sequenced, we transformed recombinant pPICZαA/hIL-1β into Pichia pastoris GS115, SMD1168 and X-33 strain via electroporation. The results showed that recombinant pPICZαA/ hIL-1β had the highest expression level in X-33 Pichia pastoris. Subsequently, rhIL-1β was purified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and identified by Western blot. Then the fermentation process was optimized to increase product yield. Under the fermentation conditions of the absorption value of fermentation liquor before induction of 600, oxygen concentration of 20%, methanol concentration of 0.25% with pH 5.0, the yield of rhIL-1β reached to 250 mg/L after 72 h induction at 26°C. After aqueous two-phase extraction combined with chromatography, the purity of rhIL-1β was 95% and the yield was up to 85%. The biological activity of rhIL-1β was detected by MTT assay, and the result showed that rhIL-1β significantly inhibited the growth and proliferation of B16 melanoma cells.
Keywords: Recombinant human interleukin-1 beta, Pichia pastoris, expression, purification, B16 melanoma cell.
Protein & Peptide Letters
Title:High-Level Secretory Expression and Purification of Recombinant Human Interleukin 1 Beta in Pichia pastoris
Volume: 23 Issue: 8
Author(s): Pengfei Li, Ganggang Yang, Xiaofang Geng, Jinbao Shi, Bin Li, Ze Wang, Quanyi Zhang, Yajuan Yang and Cunshuan Xu
Affiliation:
Keywords: Recombinant human interleukin-1 beta, Pichia pastoris, expression, purification, B16 melanoma cell.
Abstract: As an important pro-inflammatory cytokine, interleukin-1beta (IL-1β) participates in a variety of physiological and pathological responses. In order to obtain higher yielded recombinant human interleukin-1 beta (rhIL-1β), we cloned hIL-1β cDNA sequences based on the coding sequence of human mature IL-1β. After recombinant pPICZαA/hIL-1β was separated and sequenced, we transformed recombinant pPICZαA/hIL-1β into Pichia pastoris GS115, SMD1168 and X-33 strain via electroporation. The results showed that recombinant pPICZαA/ hIL-1β had the highest expression level in X-33 Pichia pastoris. Subsequently, rhIL-1β was purified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and identified by Western blot. Then the fermentation process was optimized to increase product yield. Under the fermentation conditions of the absorption value of fermentation liquor before induction of 600, oxygen concentration of 20%, methanol concentration of 0.25% with pH 5.0, the yield of rhIL-1β reached to 250 mg/L after 72 h induction at 26°C. After aqueous two-phase extraction combined with chromatography, the purity of rhIL-1β was 95% and the yield was up to 85%. The biological activity of rhIL-1β was detected by MTT assay, and the result showed that rhIL-1β significantly inhibited the growth and proliferation of B16 melanoma cells.
Export Options
About this article
Cite this article as:
Li Pengfei, Yang Ganggang, Geng Xiaofang, Shi Jinbao, Li Bin, Wang Ze, Zhang Quanyi, Yang Yajuan and Xu Cunshuan, High-Level Secretory Expression and Purification of Recombinant Human Interleukin 1 Beta in Pichia pastoris, Protein & Peptide Letters 2016; 23 (8) . https://dx.doi.org/10.2174/0929866523666160530184936
DOI https://dx.doi.org/10.2174/0929866523666160530184936 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
Call for Papers in Thematic Issues
Therapeutic Proteins and Peptides of Plant Origin
Plants are still the major repository of biologically active substances. In the last two decades, however, natural peptides and proteins of plant origin have gained increasing attention due to their pharmacological activities over a variety of human illnesses, including those mediated by infections and parasitosis and those involving different cellular ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Therapy Stratifications and Novel Approach in Pursuit of Aids Related Kaposi’s Sarcoma Management- A paradigm for Non Invasiveness
Current Drug Delivery ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma
Current Medicinal Chemistry Nutrition and DNA Repair - Potential Molecular Mechanisms of Action
Current Cancer Drug Targets Lifelong and Prenatal Effects of Phytoestrogens
Current Bioactive Compounds Therapeutic Effects of Statins: Promising Drug for Topical and Transdermal Administration
Current Medicinal Chemistry Actinic Keratosis: Review of the Literature and New Patents
Recent Patents on Inflammation & Allergy Drug Discovery A Review: Hair Health, Concerns of Shampoo Ingredients and Scalp Nourishing Treatments
Current Pharmaceutical Biotechnology Natural Tyrosinase Inhibitors: Role of Herbals in the Treatment of Hyperpigmentary Disorders
Mini-Reviews in Medicinal Chemistry Enhanced Oral Bioavailability of The Hydrophobic Chemopreventive Agent (Sr13668) in Beagle Dogs
Current Pharmaceutical Biotechnology Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry Effects of Tea Polyphenols and their Polymers on MAPK Signaling Pathways in Cancer Research
Mini-Reviews in Medicinal Chemistry Small Molecule Complementarity As A Source of Novel Pharmaceutical Agents and Combination Therapies
Current Pharmaceutical Design Meet Our Editor
Current Gene Therapy A2A Adenosine Receptor Agonists and their Potential Therapeutic Applications. An Update
Current Medicinal Chemistry Lifestyle Factors and MicroRNAs: A New Paradigm in Cancer Chemoprevention
MicroRNA A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
Current Drug Targets